-
2024-514826-22-00
7
2022-12-05
Part A: Patients with advanced solid tumors or lymphomas.
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2024-511884-27-00
3
2022-11-09
CD205+ve recurrent and/or metastatic tumor types including but not lim
-
2023-503442-30-00
5
2022-10-14
Multiple Myeloma
-
2023-510346-25-00
5
2022-09-01
Hypereosinophilic Syndrome (HES)
-
2023-506517-22-00
9
2022-08-31
Advanced or Metastatic Colorectal Cancer
-
2023-503267-42-00
5
2022-06-10
Patients with a histological diagnosis of mismatch- repair deficient h
-
2022-502373-42-00
5
2022-04-25
Oligorecurrent hormone-sensitive prostate cancer patients
-
2024-516336-97-00
4
2022-02-21
METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
-
2023-504152-97-00
5
2021-11-26
Generalized Myasthenia Gravis
-
2024-511246-39-00
1
2021-07-27
Solid tumours with HER2 aberrations
-
2024-515625-29-00
5
2020-06-16
Apnea of prematurity
-
2023-508956-20-00
5
2020-03-12
Hidradenitis suppurativa
-
2023-508689-14-00
5
2019-09-16
Sickle cell disease
-
2024-518568-11-00
4
2019-02-04
Hematological malignancies confirmed histologically:
- AML in morphol
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2024-513627-16-01
7
2018-03-28
Colorectal cancer metastatic
-
2024-516103-16-00
4
2015-12-04
Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
-
2025-522105-38-00
5
2026-02-02
Chronic Hepatitis Delta Infection
-
2025-521970-33-00
5
2025-12-19
Pulmonary Arterial Hypertension (PAH)
-
2025-522598-12-00
10
2025-12-17
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
-
2023-506146-23-00
4
2025-11-17
Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder
-
2024-518457-42-00
4
2025-08-28
chronic kidney disease
-
2024-519319-32-00
7
2025-08-27
Urinary Tract Infections